Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epilepsy, Partial: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Epilepsy, Partial: 3 US clinical trials tracked, none currently recruiting.
Epilepsy, Partial is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Pharma, running 1 of these trials.
Enrollment posture brief
Registry condition epilepsy-partial
OPEN 0 | RECR 0% | LATE 1 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Epilepsy, Partial has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epilepsy, Partial on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epilepsy, Partial is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
GlaxoSmithKline
NCT00355082
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Pfizer
NCT00141414
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
UCB Pharma
NCT00152503
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Epilepsy, Partial records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epilepsy, Partial trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epilepsy, Partial page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Epilepsy, Partial trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- UCB Pharma sponsors the most Epilepsy, Partial trials on record, review their full trial history before evaluating a specific study. See UCB Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epilepsy, Partial condition card totals 3 registered trials; most-linked intervention lamotrigine, 250 mg/day; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.